Page last updated: 2024-10-24
carvedilol and Dyslipidemia
carvedilol has been researched along with Dyslipidemia in 2 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "We aimed to investigate the acute and chronic effects of carvedilol on insulin resistance in high-fructose, high-fat diet (HFrHFD) - fed mice and the implication of the β-arrestin2 pathway." | 4.12 | Acute and chronic metabolic effects of carvedilol in high-fructose, high-fat diet-fed mice: implication of β-arrestin2 pathway. ( Ahmed, HMS; Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF; Mohamed, SG; Rezk, AM, 2022) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Ahmed, HMS | 1 |
| Mohamed, SG | 1 |
| Ibrahim, WS | 1 |
| Rezk, AM | 1 |
| Mahmoud, AAA | 1 |
| Mahmoud, MF | 1 |
| Ibrahim, IAAE | 1 |
| Bakris, GL | 1 |
| Tarka, EA | 1 |
| Waterhouse, B | 1 |
| Goulding, MR | 1 |
| Madan, A | 1 |
| Anderson, KM | 1 |
| St John Sutton, M | 1 |
| Miller, AB | 1 |
| Reichek, N | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Re[NCT00108082] | Phase 3 | 287 participants (Actual) | Interventional | 2005-01-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12
LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams (g) (Mean) |
|---|
| Carvedilol CR | -13.74 |
| Atenolol | -14.17 |
| Lisinopril | -17.17 |
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12
LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams per meters squared (g/m^2) (Mean) |
|---|
| Carvedilol CR | -20.35 |
| Atenolol | -20.06 |
| Lisinopril | -18.48 |
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12
LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the Last Observation Carried Forward [LOCF] analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams per meters squared (g/m^2) (Mean) |
|---|
| Carvedilol CR | -6.34 |
| Atenolol | -6.67 |
| Lisinopril | -7.94 |
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12
LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was available)
| Intervention | g/m raised to 2.7 (g/(m^2.7)) (Mean) |
|---|
| Carvedilol CR | -11.78 |
| Atenolol | -12.51 |
| Lisinopril | -11.61 |
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12
LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | g/m raised to 2.7 (g/(m^2.7)) (Mean) |
|---|
| Carvedilol CR | -3.19 |
| Atenolol | -3.37 |
| Lisinopril | -3.98 |
Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12
LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | grams (Mean) |
|---|
| Carvedilol CR | -45.76 |
| Atenolol | -40.56 |
| Lisinopril | -38.58 |
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12
Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Intervention | percentage of change (Geometric Mean) |
|---|
| Carvedilol CR | -27.1 |
| Atenolol | -20.1 |
| Lisinopril | -21.5 |
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12
BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) [Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value]. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used
| Intervention | percentage of change (Geometric Mean) |
|---|
| Carvedilol CR | 51.7 |
| Atenolol | 48.3 |
| Lisinopril | -39.1 |
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12
CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Intervention | percentage of change (Geometric Mean) |
|---|
| Carvedilol CR | -10.63 |
| Atenolol | -3.22 |
| Lisinopril | 2.70 |
Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12
LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume). (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | milliliters (mL) (Mean) |
|---|
| LV E-volume | LV A-volume |
|---|
| Atenolol | 6.763 | -0.565 |
,| Carvedilol CR | 0.364 | -0.513 |
,| Lisinopril | -3.406 | 1.088 |
Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | milliliters (mL) (Mean) |
|---|
| LV End Systolic Volume | LV End Diastolic Volume | LV Ejection Fraction |
|---|
| Atenolol | -4.74 | -3.64 | 2.33 |
,| Carvedilol CR | -3.38 | -3.07 | 1.03 |
,| Lisinopril | -5.34 | -9.37 | 0.63 |
Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | milliliters (mL) (Mean) |
|---|
| LV End Systolic Volume | LV End Diastolic Volume | LV Ejection Fraction |
|---|
| Atenolol | -4.29 | -2.45 | 2.16 |
,| Carvedilol CR | -1.44 | -2.86 | 0.08 |
,| Lisinopril | -3.04 | -7.45 | -0.01 |
Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12
Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
| Intervention | mmHg (millimeters of mercury) (Mean) |
|---|
| Systolic blood pressure | Diastolic blood pressure |
|---|
| Atenolol | -21.12 | -14.05 |
,| Carvedilol CR | -21.32 | -12.77 |
,| Lisinopril | -22.53 | -11.13 |
Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12
Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Intervention | percentage of change (Geometric Mean) |
|---|
| Total cholesterol | Low-density lipid cholesterol | High-density lipid cholesterol | Triglycerides |
|---|
| Atenolol | -1.3 | -4.0 | -4.7 | 7.1 |
,| Carvedilol CR | 0.7 | 0.0 | -4.3 | 11.0 |
,| Lisinopril | -1.7 | -2.7 | -1.5 | 6.2 |
Other Studies
2 other studies available for carvedilol and Dyslipidemia